Hypertrophic Cardiomyopathy versus Storage Diseases with Myocardial Involvement
One of the main causes of heart failure is cardiomyopathies. Among them, the most common is hypertrophic cardiomyopathy (HCM), characterized by thickening of the left ventricular muscle. This article focuses on HCM and other cardiomyopathies with myocardial hypertrophy, including Fabry disease, Pomp...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/17/13239 |
| _version_ | 1797582487846649856 |
|---|---|
| author | Anna Burban Szymon Pucyło Aleksandra Sikora Grzegorz Opolski Marcin Grabowski Agnieszka Kołodzińska |
| author_facet | Anna Burban Szymon Pucyło Aleksandra Sikora Grzegorz Opolski Marcin Grabowski Agnieszka Kołodzińska |
| author_sort | Anna Burban |
| collection | DOAJ |
| description | One of the main causes of heart failure is cardiomyopathies. Among them, the most common is hypertrophic cardiomyopathy (HCM), characterized by thickening of the left ventricular muscle. This article focuses on HCM and other cardiomyopathies with myocardial hypertrophy, including Fabry disease, Pompe disease, and Danon disease. The genetics and pathogenesis of these diseases are described, as well as current and experimental treatment options, such as pharmacological intervention and the potential of gene therapies. Although genetic approaches are promising and have the potential to become the best treatments for these diseases, further research is needed to evaluate their efficacy and safety. This article describes current knowledge and advances in the treatment of the aforementioned cardiomyopathies. |
| first_indexed | 2024-03-10T23:21:58Z |
| format | Article |
| id | doaj.art-e353e84433284a048c6b9f352df7742e |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T23:21:58Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-e353e84433284a048c6b9f352df7742e2023-11-19T08:14:25ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-08-0124171323910.3390/ijms241713239Hypertrophic Cardiomyopathy versus Storage Diseases with Myocardial InvolvementAnna Burban0Szymon Pucyło1Aleksandra Sikora2Grzegorz Opolski3Marcin Grabowski4Agnieszka Kołodzińska5First Department of Cardiology, Medical University of Warsaw, ul. Banacha 1A, 02-097 Warszawa, PolandFirst Department of Cardiology, Medical University of Warsaw, ul. Banacha 1A, 02-097 Warszawa, PolandFirst Department of Cardiology, Medical University of Warsaw, ul. Banacha 1A, 02-097 Warszawa, PolandFirst Department of Cardiology, Medical University of Warsaw, ul. Banacha 1A, 02-097 Warszawa, PolandFirst Department of Cardiology, Medical University of Warsaw, ul. Banacha 1A, 02-097 Warszawa, PolandFirst Department of Cardiology, Medical University of Warsaw, ul. Banacha 1A, 02-097 Warszawa, PolandOne of the main causes of heart failure is cardiomyopathies. Among them, the most common is hypertrophic cardiomyopathy (HCM), characterized by thickening of the left ventricular muscle. This article focuses on HCM and other cardiomyopathies with myocardial hypertrophy, including Fabry disease, Pompe disease, and Danon disease. The genetics and pathogenesis of these diseases are described, as well as current and experimental treatment options, such as pharmacological intervention and the potential of gene therapies. Although genetic approaches are promising and have the potential to become the best treatments for these diseases, further research is needed to evaluate their efficacy and safety. This article describes current knowledge and advances in the treatment of the aforementioned cardiomyopathies.https://www.mdpi.com/1422-0067/24/17/13239hypertrophic cardiomyopathyFabry diseasePompe diseaseDanon diseasegeneticsgene therapies |
| spellingShingle | Anna Burban Szymon Pucyło Aleksandra Sikora Grzegorz Opolski Marcin Grabowski Agnieszka Kołodzińska Hypertrophic Cardiomyopathy versus Storage Diseases with Myocardial Involvement International Journal of Molecular Sciences hypertrophic cardiomyopathy Fabry disease Pompe disease Danon disease genetics gene therapies |
| title | Hypertrophic Cardiomyopathy versus Storage Diseases with Myocardial Involvement |
| title_full | Hypertrophic Cardiomyopathy versus Storage Diseases with Myocardial Involvement |
| title_fullStr | Hypertrophic Cardiomyopathy versus Storage Diseases with Myocardial Involvement |
| title_full_unstemmed | Hypertrophic Cardiomyopathy versus Storage Diseases with Myocardial Involvement |
| title_short | Hypertrophic Cardiomyopathy versus Storage Diseases with Myocardial Involvement |
| title_sort | hypertrophic cardiomyopathy versus storage diseases with myocardial involvement |
| topic | hypertrophic cardiomyopathy Fabry disease Pompe disease Danon disease genetics gene therapies |
| url | https://www.mdpi.com/1422-0067/24/17/13239 |
| work_keys_str_mv | AT annaburban hypertrophiccardiomyopathyversusstoragediseaseswithmyocardialinvolvement AT szymonpucyło hypertrophiccardiomyopathyversusstoragediseaseswithmyocardialinvolvement AT aleksandrasikora hypertrophiccardiomyopathyversusstoragediseaseswithmyocardialinvolvement AT grzegorzopolski hypertrophiccardiomyopathyversusstoragediseaseswithmyocardialinvolvement AT marcingrabowski hypertrophiccardiomyopathyversusstoragediseaseswithmyocardialinvolvement AT agnieszkakołodzinska hypertrophiccardiomyopathyversusstoragediseaseswithmyocardialinvolvement |